Results from additional trials are expected throughout 2026
Despite their popularity on social media, these medications carry significant risks and can be harmful to those who do not need them
Coverage for GLP-1s for weight loss is not required under the federal Employee Retirement Income Security Act (ERISA)
start with a lower dose and increase gradually based on tolerance
And as I said, GIP came along but couldn't really explain everything
CLINICAL EVIDENCE OF THE USE OF GLP-1RAs IN BAD TREATMENT Two patients experiencing complete remission of BAD symptoms after initiating liraglutide treatment for type 2 diabetes and obesity, respectively (15), inspired us to compare the effect of liraglutide and the current standard-of-care treatment of BAD, the bile acid sequestrant colesevelam, in patients with idiopathic or postcholecystectomy BAD in a 6-week double-dummy, double-blind RCT (21)